Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Substance Withdrawal Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

NCT00106106
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions
NMR-spectroscopy, Oral acamprosate
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

NCT00158132
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Propranolol, Amantadine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder

NCT04092101
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cigarettes with varying nicotine content, E-Cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Alcohol Relapse Prevention

NCT02349477
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Results available

Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder

NCT05226130
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Not applicable Interventional Results available

Treating Alcohol Withdrawal With Oral Baclofen

NCT00597701
View directory record Official record
Conditions
Alcohol Withdrawal Delirium
Interventions
Baclofen, Placebo, Lorazepam
Drug
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 21, 2026, 2:09 AM EDT
Completed No phase listed Observational

Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms

NCT01603992
View directory record Official record
Conditions
Cannabis Abuse, Cannabis Dependence
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Catonsville, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 3 Interventional

Lofexidine for Inpatient Opiate Detox

NCT00235729
View directory record Official record
Conditions
Opiate Addiction
Interventions
Lofexidine, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Cerritos, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2009 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

NCT00000358
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 1Phase 2 Interventional

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

NCT02431728
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Melatonin, Matched Placebo
Dietary Supplement
Lead sponsor
Duquesne University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oxytocin Treatment of Opioid Dependence

NCT02548728
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal
Interventions
Intranasal Oxytocin Spray, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 21, 2026, 2:09 AM EDT
Not listed No phase listed Observational

Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing

NCT05307458
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

NCT02643355
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Olanzapine, Clonidine
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 21, 2026, 2:09 AM EDT
Recruiting Not applicable Interventional

Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder

NCT07079826
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Use Disorder (OUD)
Interventions
Sparrow Link (Active tAN), Sparrow Link (Sham tAN)
Device
Lead sponsor
Payel Roy
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 2:09 AM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

NCT04556552
View directory record Official record
Conditions
Substance-Related Disorders, Substance Use Disorders, Substance Abuse, Intravenous, Substance Withdrawal, Substance Abuse, Opioid-use Disorder, Opioid Use Disorder, Severe, Opioid Use
Interventions
Non invasive VN stimulation (nVNS), Oxygen (15-O) Water, Sham Stimulation
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

NCT00749658
View directory record Official record
Conditions
Nicotine Dependence, Nicotine Withdrawal
Interventions
Bupropion, Varenicline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 21, 2026, 2:09 AM EDT
Recruiting Phase 2Phase 3 Interventional

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

NCT07148843
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
Interventions
Cannabidiol (CBD), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

THC Crossover Study

NCT04429568
View directory record Official record
Conditions
THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified, Cigarette Smoking, Tobacco Use, Nicotine Dependence, Nicotine Withdrawal, Cardiovascular Risk Factor
Interventions
Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

NCT00521248
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
buprenorphine, Oral morphine solution
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Withdrawal and Reward Processing

NCT05041959
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence, Nicotine Withdrawal
Interventions
Smoking Abstinence, Ad Lib Smoking
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Innovative Intervention for OUD Treatment

NCT04325659
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Interventions
Bridge Device, Lofexidine, Placebo, Sham Bridge Device
Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 2:09 AM EDT